https://burns-media.com/biotech/ The catalyst calendar for biotech investors. Published weekday mornings by Burns Media. en-us © 2026 Burns Media 60 Wed, 03 Jun 2026 15:54:30 +0000 https://burns-media.com/assets/social/biotech_fda.png https://burns-media.com/biotech/ https://burns-media.com/biotech/archive/2026-05-22 https://burns-media.com/biotech/archive/2026-05-22 Fri, 22 May 2026 07:00:00 +0000 Biogen and Denali drop Parkinson's drug; Merck's ADC shows promise in lung cancer. Biogen and Denali's LRRK2 inhibitor, BIIB122, has failed in a Phase 2b trial for Parkinson's, prompting the companies to discontinue the program for non-genetic patients. Meanwhile, Merck's partnership with Kelun-Biotech reports a 65% reduction in tumor progression for lung cancer patients in a Phase 3 study.

Top stories

• Biogen, Denali drop drug in non-genetic Parkinsons after mid-stage study flop
  The Phase 2b trial for BIIB122 missed its primary endpoint, leading Biogen and Denali to halt further development in early Parkinson's patients. This setback raises questions about the future of LRRK2 inhibitors and their competitive landscape against other therapies.
• Merck partner Kelun outlines Phase 3 lung cancer success in China study
  Kelun-Biotech's experimental ADC, sac-TMT, demonstrated a 65% reduction in tumor progression in lung cancer patients, raising hopes for similar efficacy in Western populations. The study's success could bolster Merck's (NYSE: MRK) ADC portfolio amid increasing competition.
• Weight-loss drugs from Lilly, Novo linked to stalling cancer: report
  Recent studies suggest that weight-loss medications from Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) may hinder cancer progression. The implications for both companies could be significant as they navigate regulatory landscapes and market perceptions.
• AI Designs Miniprotein Switches for GPCR Targeting
  New AI-designed miniproteins precisely modulate GPCR signaling and reveal a new "receptor diversion" microscopy-based screening system for targeting receptors long considered difficult to drug. This advancement could open new avenues for drug discovery and development.

Quick hits

• NervGen Pharma prices 24M share public offering; warrants at $3.68.
• Akari Therapeutics gains on positive preclinical data for cancer therapy.
• Zymeworks is well-positioned to capitalize on ADC demand growth.

Read the full briefing →

]]> Biotech https://burns-media.com/biotech/archive/2026-05-21 https://burns-media.com/biotech/archive/2026-05-21 Thu, 21 May 2026 07:00:00 +0000 Eli Lilly's latest trial results could reshape obesity treatments. Eli Lilly's next-generation obesity drug achieved weight loss comparable to bariatric surgery in late-stage trials, but faced dropout issues due to side effects. This could redefine market competition in obesity therapeutics.

Top stories

• Lillys triple-G drug leads to bariatric-surgery levels of weight loss in trial
  Eli Lilly's obesity drug, retatrutide, demonstrated significant weight loss, with some patients losing over 20% of their body weight. However, dropout rates due to side effects raise concerns about long-term tolerability and market acceptance.
• Bayer granted priority review for Kerendia label expansion in U.S.
  Bayer's Kerendia, indicated for chronic kidney disease, is under priority review by the FDA for expanded labeling, which could enhance its market position. The review is expected to conclude by Q3 2026.
• Immix Biopharma prices $150M stock offering at $8.94/share
  Immix Biopharma has successfully priced a $150 million stock offering to fund its AL amyloidosis therapy development. The offering price represents a 5% discount to the last closing price, reflecting market conditions.
• Bristol Myers deepens AI investment with Anthropic deal
  Bristol Myers Squibb has partnered with Anthropic to enhance its AI capabilities, focusing on drug discovery and development processes. This collaboration follows a trend of big pharma investing heavily in AI technologies.
• BMS eyes new campus in Texas; Novartis looks to evict tenant at Slovenian campus
  Bristol Myers Squibb is considering a new pharmaceutical campus in Houston, Texas, to support its expanding operations. This move reflects a strategic push to enhance its manufacturing capabilities in a favorable business environment.

Quick hits

• Relay Therapeutics downgraded due to competitive risks despite encouraging data.
• Gilead is reportedly considering a merger with a smaller biotech to bolster its pipeline.
• Belite Bio aims to complete its Stargardt NDA rolling submission by Q2 2026.

Read the full briefing →

]]> Biotech https://burns-media.com/biotech/archive/2026-05-20 https://burns-media.com/biotech/archive/2026-05-20 Wed, 20 May 2026 07:00:00 +0000 Guardant360's FDA nod positions Guardant for growth in cancer diagnostics. Guardant Health just secured FDA approval for its Guardant360 Liquid CDx cancer test. This positions the company to capture a larger share of the rapidly growing liquid biopsy market.

Top stories

• Guardant wins FDA nod for Guardant360 Liquid CDx cancer test
  The FDA's approval of Guardant360 enables non-invasive cancer detection and monitoring, enhancing Guardant's competitive edge in the $5 billion liquid biopsy market. This positions Guardant against rivals like Grail and Freenome, who are also advancing liquid biopsy technologies.
• ImmunityBio rises as Anktiva label expansion undergoes FDA review
  ImmunityBio's Anktiva label expansion, currently under FDA review, could significantly enhance its market position in immunotherapy for bladder cancer. The company is seeking to broaden indications for Anktiva, which previously showed promise in Phase 2 trials.
• Parabilis reveals IPO plans the day after Regeneron deal as listings heat up
  Parabilis Medicines, the decade-old and well-funded 'undruggable' biotech out of Greg Verdine's Harvard lab, seeks to become the 12th drug developer to conduct an initial public offering this year. The company aims to leverage recent momentum in the biotech IPO market.
• BioMarin drug acquired in buyout misses goal in rare disease study
  BioMarin's recently acquired drug failed to meet its primary endpoint in a key trial for ENPP1 deficiency, raising concerns about its regulatory approval path. This setback could impact BioMarin's (BMRN) growth strategy in rare diseases.
• Google DeepMind and Edison Are Building the AI Scientist
  Google DeepMind and Edison are collaborating to develop AI scientists that can automate the scientific method, potentially revolutionizing drug discovery timelines. This initiative aims to integrate hypothesis generation, experimental design, and data interpretation.

Quick hits

• Kraig Biocraft Labs has developed an immortalized silk gland cell line, enhancing bioprocessing capabilities.
• NRx Pharmaceuticals faces a 'sell' rating following multiple failures in its depression market strategy.
• TrumpRx adds over 600 generic drugs to its platform, expanding its direct-to-consumer offerings.

Read the full briefing →

]]> Biotech https://burns-media.com/biotech/archive/2026-05-19 https://burns-media.com/biotech/archive/2026-05-19 Tue, 19 May 2026 07:00:00 +0000 Relay's Phase 2 results and InMed's merger signal shifts in biotech strategies. Relay Therapeutics' zovegalisib shows early efficacy against vascular anomalies, positioning it ahead of Novartis' Vijoice. Meanwhile, InMed and Mentari have announced an all-stock merger deal.

Top stories

• Relay's PI3Kb1 inhibitor clears efficacy bar in Phase 2 study
  Relay Therapeutics reported that zovegalisib met efficacy endpoints in its Phase 2 trial for vascular anomalies, surpassing Wall Street expectations. This positions Relay to potentially expand its R&D focus beyond breast cancer, with significant implications for its stock (ticker: RLAY).
• InMed and Mentari announce all-stock merger deal
  InMed Pharmaceuticals (INM) and Mentari's merger aims to consolidate resources and expand their pipeline, with a focus on rare disease therapies. This strategic move comes as both companies seek to enhance their market positions amid increasing competition.
• BioMarin's rare disease therapy shows no clinical benefit in Phase 3 test
  BioMarin's Phase 3 trial for its enzyme replacement therapy targeting ENPP1 deficiency failed to demonstrate significant clinical benefits, raising concerns about the future of this treatment. This setback could impact the company's stock performance (ticker: BMRN) as investors reassess its pipeline.
• Bayer wins FDA priority review for asundexian in stroke and TIA patients
  Bayer's asundexian, a novel oral anticoagulant, has received FDA priority review, aiming for a PDUFA date in Q4 2026. This drug could significantly impact treatment protocols for stroke and TIA, with potential annual sales projected to exceed $1 billion.
• Relay drug shows early promise against rare blood vessel diseases
  While early, the findings suggest the therapy could be superior to Novartis’ Vijoice at treating “vascular anomalies,” a cluster of chronic conditions with few available treatments. This positions Relay Therapeutics to potentially disrupt the current market.

Quick hits

• FDA's approval of AstraZeneca's Baxfendy could generate over $5B in annual sales.
• Regeneron inks a $125M deal with Parabilis to target elusive drug candidates.
• Amgen faces scrutiny as Japan warns against new prescriptions for Tavneos amid toxicity concerns.

Read the full briefing →

]]> Biotech https://burns-media.com/biotech/archive/2026-05-18 https://burns-media.com/biotech/archive/2026-05-18 Mon, 18 May 2026 07:00:00 +0000 Regeneron’s melanoma trial flops while AstraZeneca secures key FDA approval for hypertension drug. Regeneron’s fianlimab failed to outperform Keytruda in a late-stage melanoma trial, wiping billions off its market cap. Meanwhile, AstraZeneca's baxdrostat received FDA approval, bolstering its revenue goals.

Top stories

• Regeneron immunotherapy combo comes up short in melanoma trial
  Regeneron's two-drug regimen of fianlimab and Libtayo did not outperform Merck's Keytruda in a late-stage study, resulting in a $6 billion drop in market value. Analysts had expected positive results, making this a significant setback for Regeneron.
• FDA approves AstraZeneca’s baxdrostat for certain patients with hypertension
  The FDA has approved baxdrostat, a key product for AstraZeneca, which aims to reach $80 billion in revenue by 2030. The approval is crucial as it addresses a significant market need for hypertension treatments.
• Quince announces acquisition of Orphai and up to $187M private placement
  Quince is acquiring Orphai to enhance its pulmonary pipeline and is initiating a private placement of up to $187 million. This move aims to accelerate the development of innovative therapies in the pulmonary space.
• NRx Pharmaceuticals targets summer 2026 KETAFREE approval
  NRx Pharmaceuticals is scaling production to 1 million units per batch, aiming for KETAFREE approval by summer 2026. This ambitious target could significantly impact its market positioning in the treatment of COVID-related depression.
• The Supreme Court won't take up drugmakers' IRA cases
  The Supreme Court's decision not to review cases from AstraZeneca and others regarding Medicare drug price negotiations means the IRA remains intact. This ruling could have long-term implications for drug pricing and market dynamics.

Quick hits

• Catheter Precision reports Q1 results, showing steady growth in their cardiac monitoring business.
• CervoMed also reports Q1 results, highlighting progress in their neurological therapies.
• Regenxbio's stock tumbles despite positive pivotal data for its DMD gene therapy candidate RGX-202.

Read the full briefing →

]]> Biotech https://burns-media.com/biotech/archive/2026-05-15 https://burns-media.com/biotech/archive/2026-05-15 Fri, 15 May 2026 07:00:00 +0000 2026 is shaping up to be a record year for biopharma M&A as mid-size firms lead the charge. Mid-cap American drugmakers and family-owned pharma groups are stepping up their acquisition strategies. With 2026 poised to be a banner year for biopharma M&A, the landscape is shifting.

Top stories

• Mid-size companies are stepping up deal hunts
  Mid-sized American and European drugmakers are increasingly pursuing acquisitions, with 2026 expected to be one of the most active years for biopharma M&A. This trend signals a shift from traditional big pharma dominance in the market.
• Regenxbio outlines accelerated approval path for RGX-202
  Regenxbio (RGNX) plans to pursue accelerated approval for RGX-202 following positive Phase III trial results. The pivotal study met its primary endpoint, indicating potential for significant market entry in 2027.
• Celcuity targets July 17 FDA decision for gedatolisib
  Celcuity (CELC) is awaiting an FDA decision on gedatolisib, with a target date set for July 17, 2026. The drug is positioned to treat specific cancer types, potentially impacting treatment paradigms.
• AstraZeneca Phase 3 trial shows success in bladder cancer
  AstraZeneca (AZN) reported that its combination therapy of Imfinzi and Padcev improved survival rates in bladder cancer patients compared to standard care. The company plans to seek regulatory approval based on these promising results.
• Encapsulated bacteria platform releases therapeutics in response to infection
  Researchers have developed an implantable living materials platform that uses infection-sensing bacteria to release therapeutic agents when pathogens are detected. This innovative approach could revolutionize infection management.

Quick hits

• Daré Bioscience targets 2,500 exposure cycles for Ovaprene in Phase III by year-end.
• Create Medicines raised $122M to advance RNA-based CAR-T therapies.
• Biogen pushes ahead with BIIB080 for Alzheimer's despite previous trial failures.

Read the full briefing →

]]> Biotech https://burns-media.com/biotech/archive/2026-05-14 https://burns-media.com/biotech/archive/2026-05-14 Thu, 14 May 2026 07:00:00 +0000 New trial data impacts Regenxbio; Biogen's Alzheimer's drug misses goals. Regenxbio's Duchenne muscular dystrophy gene therapy met pivotal study benchmarks, positioning it for a 2027 FDA submission. Meanwhile, Biogen's anti-tau Alzheimer's candidate faltered in its Phase 2 trial.

Top stories

• Regenxbio hits Duchenne gene therapy milestone, eyes 2027 FDA approval
  Regenxbio announced that its gene therapy for Duchenne muscular dystrophy met pivotal study criteria, setting the stage for FDA submission in 2027. The company aims to become the second to market for this indication, following Sarepta Therapeutics (SRPT).
• Biogen's anti-tau Alzheimer's drug misses Phase 2 goal, but claims signs of efficacy
  Biogen's BIIB080 failed to meet its primary endpoint in a Phase 2 study but reported some signs of efficacy, prompting the company to advance to pivotal studies. The mixed results raise questions about the drug's viability against competitors like Eli Lilly (LLY).
• CVS unit Omnicare to be sold to GenieRx after court approval
  CVS Health's Omnicare has received court approval for its sale to GenieRx, a move expected to streamline operations within CVS's pharmacy services. The sale is part of CVS's ongoing strategy to optimize its portfolio amid competitive pressures.
• STAT+: CREATE Medicines raises $122 million for CAR-T development
  CREATE Medicines secured $122 million to advance its CAR-T therapies, aiming to enhance treatment options for hematologic cancers. This funding will support the development of its lead candidates through clinical trials.

Quick hits

• Auxly Cannabis reported Q1 results, revealing ongoing challenges in the market.
• Pyxis Oncology's GAAP EPS of -$0.37 missed expectations by $0.01, reflecting ongoing financial pressures.
• Valneva plans to cut 10-15% of its workforce due to declining vaccine demand post-COVID.

Read the full briefing →

]]> Biotech https://burns-media.com/biotech/archive/2026-05-13 https://burns-media.com/biotech/archive/2026-05-13 Wed, 13 May 2026 07:00:00 +0000 Tessera's new therapy could disrupt the sickle cell treatment landscape. Tessera Therapeutics has unveiled impressive data for its gene editing therapy targeting sickle cell disease, potentially shifting the treatment paradigm away from complex cell-based therapies.

Top stories

• Tessera reveals strongest data yet for in vivo sickle cell therapy
  Tessera's experimental gene editing drug shows promise as a simple infusion treatment for sickle cell disease, competing with established therapies. This approach eliminates the need for complex cell engineering or chemotherapy preconditioning, appealing to a broader patient base.
• Gene Therapy ETX101 Improves Seizures and Neurodevelopment in Dravet Syndrome in Phase I/II
  ETX101 shows durable seizure reductions and early neurodevelopmental gains in children with SCN1A+ Dravet syndrome, as reported at the ASGCT Presidential Symposium. The trial highlights the potential of targeted gene regulation therapy in addressing this rare condition.
• KKR-backed GMR set for trading debut after raising $479M in IPO
  GMR's IPO raised $479 million, positioning it for a strong market entry. The funds will support its innovative approaches in the biotech space, signaling robust investor confidence.
• Seer files patent infringement lawsuit against Nanomics Biotechnology
  Seer has initiated a patent infringement lawsuit against Nanomics, alleging unauthorized use of its technology. This legal action could significantly impact Nanomics' operations and market position.
• Merck KGaA's clients are stockpiling due to Iran war, supporting guidance boost
  Merck KGaA is witnessing increased demand for its lab equipment due to stockpiling by clients amid the ongoing Iran conflict. This trend is expected to positively influence the company's financial guidance.

Quick hits

• Vor Biopharma reports Q1 results, signaling growth in its pipeline.
• Xenetic Biosciences also reports Q1 results, reflecting its ongoing development efforts.
• Lilly highlights low-dose Zepbound as a potential weight loss maintenance option.

Read the full briefing →

]]> Biotech https://burns-media.com/biotech/archive/2026-05-12 https://burns-media.com/biotech/archive/2026-05-12 Tue, 12 May 2026 07:00:00 +0000 Bristol Myers teams with Hengrui on a major licensing deal for 13 drugs. Bristol Myers Squibb just partnered with China's Hengrui Pharma in a licensing deal worth up to $15.2 billion. This collaboration includes over a dozen early-stage drugs, significantly expanding their pipeline.

Top stories

• Knit Health raises $11.6M for AI-driven healthcare solutions
  Knit Health, a UC Berkeley spinout, secured $11.6 million in seed funding to enhance healthcare operations through AI that mimics a doctor's decision-making. This funding was co-led by Uncork Capital, aiming to reshape patient care.
• Capsida remains silent on gene therapy death investigation
  Capsida's gene therapy trial faced scrutiny after a patient death, with the company not disclosing the specific brain receptor involved. This delay in transparency has raised concerns among industry experts about safety protocols.
• A year after Vertex’s big launch, pain drug research faces a pivotal moment
  Journavx has revived an area of development long considered a graveyard, with investors eager to see if new pain drugs can maintain excitement. The landscape is shifting as companies reassess their strategies in pain management.
• Bristol Myers and Hengrui Pharma ink $15.2B licensing deal
  Bristol Myers Squibb's partnership with Hengrui Pharma includes a licensing deal for 13 assets, potentially worth up to $15.2 billion. This agreement signals Bristol Myers' strategy to expand its presence in the Chinese market.
• Daiichi eyes almost $15B in oncology sales by 2030 in ADC franchise push
  Daiichi Sankyo aims to leverage its antibody-drug conjugate (ADC) franchise to reach nearly $15 billion in oncology sales by 2030. The new five-year business plan underscores its commitment to oncology innovation.

Quick hits

• SAB Biotherapeutics reports Q1 results amid ongoing challenges.
• GSK partners with Sino to enhance hepatitis B drug access in China.
• Mereo BioPharma Group's GAAP EPS of -$0.01 misses expectations by $0.01.
• Optum Rx reveals new pharmacy model emphasizing transparency for 2027.

Read the full briefing →

]]> Biotech https://burns-media.com/biotech/archive/2026-05-11 https://burns-media.com/biotech/archive/2026-05-11 Mon, 11 May 2026 07:00:00 +0000 Braveheart Bio's cardiac drug secures a second clinical win. CSL's stock plunged to its lowest level since early 2017 following a $5 billion impairment charge and a 4% cut to its revenue guidance. Meanwhile, Braveheart Bio's licensed cardiac therapy achieves a significant mid-stage trial success.

Top stories

• CSL sinks to nine-year low on revenue warning, $5B write-down
  CSL's stock dropped 9% to $55.20 after the company announced a $5 billion impairment charge and reduced its full-year revenue guidance by about 4%. This significant decline reflects ongoing challenges in its product pipeline and market conditions.
• Braveheart Bio's Hengrui-licensed cardiac drug scores second clinical win
  Braveheart Bio announced that its heart muscle therapy, licensed from Jiangsu Hengrui Pharmaceuticals, has successfully completed a mid-stage trial, marking its second clinical success. This positions Braveheart to compete directly with Cytokinetics (CYTK) in heart failure treatments.
• Zai Lab wins FDA fast track status for cancer drug zocilurtatug pelitecan
  Zai Lab's zocilurtatug pelitecan has received FDA fast track designation, which could expedite its development process. This designation is critical as Zai Lab aims to position itself in the competitive oncology market dominated by larger players like Bristol-Myers Squibb (BMY).
• Alvotech shares rise as FDA completes Reykjavik facility inspection
  Alvotech's stock surged 8% after the FDA completed its inspection of the Reykjavik manufacturing facility, a key step towards potential approval of its biosimilars. The company is positioning itself against competitors like Amgen (AMGN) and AbbVie (ABBV) in the biosimilar market.
• Medicare spending on new Alzheimer’s drugs remains significantly lower than expected
  Recent reports indicate that Medicare has spent far less than anticipated on new Alzheimer’s medications due to complexities in administration and uncertain benefits. This spending is critical as companies like Biogen (BIIB) and Eli Lilly (LLY) navigate market access challenges.

Quick hits

• Adial Pharmaceuticals reported Q1 results with a focus on its ongoing clinical trials.
• BioNTech announced recent layoffs as the biotech industry sees a slowdown in job losses.
• Fractyl Health gains approval for clinical trials of its GLP-1 gene therapy aimed at obesity.

Read the full briefing →

]]> Biotech https://burns-media.com/biotech/archive/2026-05-08 https://burns-media.com/biotech/archive/2026-05-08 Fri, 08 May 2026 07:00:00 +0000 Angelini acquires Catalyst for rare neuro drugs, enhancing U.S. market access. Angelini Pharma is acquiring Catalyst Pharmaceuticals for $4 billion, significantly enhancing its portfolio in rare CNS disorders. This deal positions Angelini for greater market access in the U.S.

Top stories

• Capricor Sues Nippon Shinyaku Over Duchenne Drug Pricing
  Capricor Therapeutics has filed a lawsuit against Nippon Shinyaku regarding a pricing flaw in their commercialization agreement for deramiocel, a cell therapy for Duchenne muscular dystrophy (DMD). This legal challenge comes as Capricor seeks to secure a favorable launch for its candidate amid a competitive landscape. The outcome could impact its market strategy and investor confidence.
• Kiora Pharmaceuticals Reports GAAP EPS of -$0.58
  Kiora Pharmaceuticals announced a GAAP EPS of -$0.58 for the latest quarter, reflecting ongoing challenges in its financial performance. Investors should note that this figure indicates a significant loss, which may affect future funding and operational strategies. The company continues to navigate a competitive landscape in the biotech sector.
• Odyssey Raises $279M in IPO, Set to Trade on Nasdaq
  Odyssey Therapeutics successfully raised $279 million from its IPO, marking a rebound after a previous withdrawal. The company, focused on autoimmune disease therapies, is now positioned to trade on the Nasdaq, enhancing its visibility and access to capital. This successful offering reflects strong investor interest in biotech innovations.

Quick hits

• EnGene's shares plummeted 80% following alarming Phase 2 bladder cancer data.
• Blackstone invests $250M in Anagram to address cystic fibrosis complications.
• Odyssey's IPO pricing reflects strong investor interest in biotech.

Read the full briefing →

]]> Biotech https://burns-media.com/biotech/archive/2026-05-07 https://burns-media.com/biotech/archive/2026-05-07 Thu, 07 May 2026 07:00:00 +0000 Aurinia beats earnings expectations; FDA reconsiders Ebvallo. Angelini Pharma is acquiring Catalyst Pharmaceuticals for $4.1 billion, significantly enhancing its neurology portfolio with three FDA-approved treatments. This deal positions Angelini to compete more effectively in the rare disease market.

Top stories

• Aurinia Pharma GAAP EPS of $0.25 beats by $0.05, revenue of $77.7M beats by $0.72M
  Aurinia reported Q1 earnings with a GAAP EPS of $0.25, exceeding expectations by $0.05. Revenue reached $77.7 million, surpassing forecasts by $0.72 million, indicating strong market demand for its lupus nephritis treatment, LUPKYNIS.
• FDA to reconsider treatment for rare cancer after its surprise rejection
  The FDA has agreed to reconsider Ebvallo, a treatment for rare cancers, after the developers addressed the agency's concerns that led to its initial rejection. This turnaround could open pathways for approval and market entry.
• Angelini fortifies neurology portfolio with $4.1B buyout of Catalyst
  Angelini Pharma's acquisition of Catalyst Pharmaceuticals for $4.1 billion will add three FDA-approved treatments for rare neurological diseases to its portfolio. This strategic move enhances Angelini's position in the growing rare disease market.
• Next-gen Duchenne drug from Entrada disappoints
  Entrada Therapeutics' next-generation Duchenne muscular dystrophy therapy failed to meet primary endpoints in an early clinical trial, raising concerns about its viability. This setback comes as multiple companies are racing to develop effective treatments in this space.
• Bayer to Acquire Perfuse for up to $2.45B, Seeing Ophthalmology Opportunity
  Bayer is acquiring Perfuse for up to $2.45 billion to bolster its ophthalmology pipeline, which includes a mid-stage glaucoma therapy. This acquisition marks Bayer's first significant drug company purchase since acquiring AskBio.

Quick hits

• Novo Nordisk raises guidance on Wegovy pill sales, projecting stronger profits.
• Madrigal's Rezdiffra sales hit $311 million, exceeding analyst expectations by $10 million.
• Amgen and AbbVie report Q1 sales impacted by Inflation Reduction Act negotiations.

Read the full briefing →

]]> Biotech https://burns-media.com/biotech/archive/2026-05-06 https://burns-media.com/biotech/archive/2026-05-06 Wed, 06 May 2026 07:00:00 +0000 Major M&A activity in biotech as Bayer expands its ophthalmology portfolio. Bayer is set to acquire Perfuse Therapeutics for $300 million, focusing on mid-stage treatments for blindness. This marks Bayer's first significant pharmaceutical acquisition in recent years.

Top stories

• UCB to Acquire Candid for up to $2.2B, Expanding Immunology Focus
  UCB's planned acquisition of Candid for up to $2.2 billion aims to enhance its portfolio in TCE antibodies for autoimmune diseases. This deal follows a previous licensing agreement with Antengene, signaling a strategic shift towards platform-based treatments.
• CellCentric Raises $220M to Advance Multiple Myeloma Treatment
  CellCentric has secured $220 million in Series D funding to expedite the development of its oral therapy for multiple myeloma. This financing comes as the company aims to address treatment gaps for patients with limited options.
• Novelty Nobility Expands AGC Biologics Deal to Take Product Candidate Through GMP Manufacturing
  Novelty Nobility is expanding its collaboration with AGC Biologics to advance a product candidate through GMP manufacturing. The project involves tech transfer from Copenhagen to Chiba, Japan, indicating a robust global manufacturing strategy.
• Blade Air Mobility Surpasses Revenue Expectations with $67.4M
  Blade Air Mobility reported a Q1 GAAP EPS of $0.03, beating estimates by $0.07, with revenues of $67.4 million exceeding expectations by $3.73 million. The results highlight the growing demand for urban air mobility solutions.
• Viridian Data Lift Prospects for Thyroid Eye Disease Drug
  New findings from Viridian's Phase 3 trial for its thyroid eye disease drug show improved efficacy in chronic patients, contrasting earlier disappointing results. Analysts view this data as competitive against Amgen's Tepezza.

Quick hits

• Novo Nordisk's Wegovy generated $2.3 billion in Q1 sales despite competition from Lilly's Foundayo.
• Intercept's INT-787 fails Phase 2 trial, marking another setback for the company.
• Pfizer's CEO Albert Bourla ruled out any plans for transformative M&A in the near term.

Read the full briefing →

]]> Biotech https://burns-media.com/biotech/archive/2026-05-05 https://burns-media.com/biotech/archive/2026-05-05 Tue, 05 May 2026 07:00:00 +0000 Cytokinetics' drug Myqorzo meets efficacy goals in heart disease study, boosting sales outlook. Cytokinetics' drug Myqorzo achieved dual efficacy endpoints in a Phase 3 trial for non-obstructive hypertrophic cardiomyopathy. This success positions the company for increased sales in a competitive market.

Top stories

• Cytokinetics drug Myqorzo meets twin efficacy goals in study of genetic heart disease
  Myqorzo, already approved for one indication, succeeded in a Phase 3 trial that could significantly enhance its market potential. Analysts anticipate this success may lead to an uptick in sales, particularly as the drug addresses a critical patient need in heart disease.
• Cytospire hauls in $83M for a new type of T cell engager
  British startup Cytospire has secured $83 million to develop its innovative 'pan-gamma delta' T cell engagers, aiming to overcome limitations of existing therapies. This funding will accelerate its R&D efforts in immuno-oncology.
• Vertex drops mRNA cystic fibrosis program over 'tolerability' issues
  Vertex Pharmaceuticals has halted its mRNA-based cystic fibrosis therapy due to tolerability challenges, mirroring issues faced by competitors in the gene therapy arena. This decision impacts its pipeline and could shift investor sentiment.
• Celcuity strengthens case for ASCO-spotlighted breast cancer drug
  Celcuity's experimental drug gedatolisib has shown promising results in PIK3CA mutant breast cancer patients, supporting a broader approval submission. This data will be highlighted at ASCO 2026, potentially influencing investor interest.
• Windward Bio gets $165M to take China-derived drug into Phase 3 asthma trial
  Windward Bio has raised $165 million to advance its asthma treatment, derived from Chinese research, into Phase 3 trials. This funding is crucial for completing the late-stage development and regulatory processes.

Quick hits

• UCB is acquiring a company specializing in antibody treatments for autoimmune diseases.
• Janux Therapeutics is rated a 'Strong Buy' as its pipeline advances while trading below cash value.
• Corcept's stock is rated a 'Strong Buy' following the FDA approval of Lifyorli and ALS Phase 3 advancement.

Read the full briefing →

]]> Biotech https://burns-media.com/biotech/archive/2026-05-04 https://burns-media.com/biotech/archive/2026-05-04 Mon, 04 May 2026 07:00:00 +0000 UCB's acquisition signals a major investment in T-cell engagers for autoimmune diseases. UCB is acquiring Candid Therapeutics for $2 billion, aiming to enhance its portfolio in autoimmune treatments. This strategic move indicates a significant shift towards bispecific antibody therapies.

Top stories

• UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseases
  UCB's $2.2 billion acquisition of Candid includes a portfolio of bispecific antibody drugs licensed from Chinese biotechs. This deal positions UCB to compete with Gilead in the burgeoning T-cell engager space, which is expected to grow significantly.
• Latus Bio raises $42 million to run Huntington’s disease trial
  Latus Bio has secured $42 million in funding to initiate a clinical trial for its gene therapy targeting Huntington's disease. This financing is crucial as the company seeks FDA approval for its innovative treatment approach.
• Celcuity’s gedatolisib beats Novartis’ Piqray in phase 3 breast cancer study
  Celcuity's gedatolisib has successfully met its primary endpoint in a phase 3 trial, outperforming Novartis' Piqray. This success allows Celcuity to move forward with a second FDA submission for the drug, enhancing its competitive positioning.
• FDA hands Pfizer, Arvinas’ Veppanu early approval for breast cancer subtype
  The FDA has granted early approval to Pfizer and Arvinas for their drug Veppanu, targeting a specific subtype of breast cancer. This approval allows the companies to advance their commercialization plans, which are still pending a partner.
• StockWatch: Patient Death, Rival’s Patent Challenge Sink Erasca Shares
  Erasca's shares plunged following a patient death linked to its treatment, compounded by a patent challenge from a competitor. The incident raises concerns about the safety profile of its drug ERAS-0015, which is under scrutiny.

Quick hits

• Esperion to go private in a $1.1B buyout by ArchiMed, following a recent acquisition.
• Deloitte's latest report reveals obesity drugs now dominate late-stage pipeline value, surpassing oncology.
• Axsome's Auvelity gains FDA approval for treating agitation in Alzheimer's patients, expanding its market reach.

Read the full briefing →

]]> Biotech https://burns-media.com/biotech/archive/2026-05-01 https://burns-media.com/biotech/archive/2026-05-01 Fri, 01 May 2026 07:00:00 +0000 Axsome's FDA win and recent IPOs signal evolving biotech landscape. Axsome's Auvelity just gained FDA approval for Alzheimer's agitation, marking a significant label expansion. Meanwhile, recent IPOs from Seaport and Hemab raised over $850 million combined.

Top stories

• Axsome wins FDA label expansion for Auvelity in Alzheimer's agitation
  Axsome's Auvelity is now approved for treating Alzheimer's agitation, expanding its market potential. The FDA decision could boost sales amid rising competition in neuropsychiatric treatments.
• Seaport, Hemab price IPOs, while Avalyn soars in Nasdaq debut
  Seaport Therapeutics and Hemab Therapeutics priced their IPOs at $15 and $17 per share, respectively, raising a combined $556 million. Avalyn Pharma debuted on Nasdaq with a 40% gain, reflecting strong investor interest.
• Approaches to Reducing Toxicity and Side Effects in Cell and Gene Therapy
  Companies are adopting diverse approaches to mitigate unwanted toxicities in cell and gene therapy. This shift is crucial as therapies advance into broader clinical applications and regulatory scrutiny.
• Going Non-Viral: Gene Delivery Enters Its Translation Era
  Advanced non-viral gene delivery systems are expanding the range of indications and therapy modalities for genetic medicines. These innovations promise safer and more effective treatment options.
• Krazati fails confirmatory trial in colorectal cancer, putting approval at risk
  Bristol Myers Squibb's Krazati has failed its confirmatory trial in second-line colorectal cancer, jeopardizing its previously granted accelerated approval. The company must now reassess its strategy in this indication.

Quick hits

• Amgen raises 2026 revenue guidance to $37.1B-$38.5B amidst MariTide Phase III expansion.
• Pacira outlines 2026 revenue guidance of $745M-$770M while advancing PCRX-201 Phase II milestones.
• Boehringer appoints Christie Bloomquist as SVP for corporate affairs, signaling strategic leadership changes.

Read the full briefing →

]]> Biotech https://burns-media.com/biotech/archive/2026-04-30 https://burns-media.com/biotech/archive/2026-04-30 Thu, 30 Apr 2026 07:00:00 +0000 Chiesi's buyout of KalVista reflects strong interest in rare disease therapies. Chiesi Pharmaceuticals just agreed to acquire KalVista for $1.9 billion, reflecting a surge in M&A activity in the biotech sector. This move highlights the industry's ongoing focus on rare disease treatments.

Top stories

• Chiesi to buy KalVista in $1.9B deal for rare disease drug
  Chiesi will pay $27 per share for KalVista Pharmaceuticals, which has an approved drug for hereditary angioedema. This acquisition marks the fifth biotech purchase this week, signaling strong interest in innovative therapies.
• Novartis unveils North Carolina factory as final new build in $23B US expansion
  Novartis has announced plans for a new factory in North Carolina, completing its $23 billion investment in US manufacturing. This facility aims to boost the production capacity for its growing portfolio.
• FDA, AstraZeneca prep for oncology adcomm
  The FDA is set to hold its first oncology advisory committee meeting in nine months, focusing on AstraZeneca's new cancer therapies. This meeting could influence upcoming drug approvals and market strategies.
• Avalyn, in pursuit of better lung drugs, banks $300M in an IPO
  Avalyn Pharmaceuticals has raised $300 million in its IPO to develop inhalable therapies for pulmonary fibrosis. The funds will accelerate its clinical programs targeting this underserved area.
• Bioprocessing Applications Laboratory Opened in Korea by Ecolab Life Sciences
  Ecolab Life Sciences has launched its Bioprocessing Applications Laboratory in Korea to support local biomanufacturers. This facility aims to enhance collaboration and expedite biomanufacturing processes across Asia.

Quick hits

• Pfizer's Elrexfio shows positive Phase 3 results in multiple myeloma.
• Teva's $700M acquisition of Emalex marks its largest deal in a decade.

Read the full briefing →

]]> Biotech https://burns-media.com/biotech/archive/2026-04-29 https://burns-media.com/biotech/archive/2026-04-29 Wed, 29 Apr 2026 07:00:00 +0000 CEO Luke Miels hints at potential restructuring based on late-stage trial outcomes. GSK faces a pivotal year with several key Phase 3 readouts on the horizon. CEO Luke Miels indicated that poor results could trigger a team reorganization.

Top stories

• AstraZeneca halts late-stage trials due to efficacy issues
  AstraZeneca has stopped multiple mid- and late-stage trials, potentially curtailing its pipeline's life-cycle extensions. This decision follows disappointing efficacy results from recent studies.
• Regeneron beats earnings estimates with strong Q1 performance
  Regeneron reported a non-GAAP EPS of $9.47, exceeding estimates by $0.57, with revenues of $3.61B, beating expectations by $130M. The solid performance was driven by strong sales of EYLEA and other key products.
• MPM BioImpact focuses on China drugs for global expansion
  MPM BioImpact is advancing its strategy by acquiring three drug programs from its portfolio company K2 Therapeutics, aiming to bring China-originated drugs to international markets. This move highlights the growing importance of the Chinese biotech landscape.
• Boehringer's obesity drug shows significant weight loss in Phase 3
  Boehringer Ingelheim's dual-acting obesity treatment, Survodutide, demonstrated a 16.6% weight loss in Phase 3 trials, with indications it may also help preserve muscle mass. This positions it as a potential competitor to Novo Nordisk's Wegovy.

Quick hits

• NeoGenomics projects 2026 revenue of $797M-$803M post-approval of PanTracer Liquid MolDX.
• GSK's Q1 performance was bolstered by HIV and cancer drugs, despite general medicine weaknesses.
• FDA's new pilot program aims to collect real-time clinical trial data to enhance review processes.

Read the full briefing →

]]> Biotech https://burns-media.com/biotech/archive/2026-04-28 https://burns-media.com/biotech/archive/2026-04-28 Tue, 28 Apr 2026 07:00:00 +0000 Lilly's partnership aims to advance next-gen gene editing technologies. Eli Lilly just secured a gene therapy partnership with Profluent potentially worth $2.25 billion. This deal aims to leverage AI-designed enzymes for advanced genetic medicine applications.

Top stories

• Eli Lilly inks gene therapy deal worth up to $2.25B with Profluent
  The partnership focuses on developing next-generation gene editors that could surpass CRISPR technology. Profluent's AI-designed enzymes aim to enhance gene insertion capabilities, significantly impacting genetic medicine. This collaboration could position Lilly as a leader in innovative gene therapies.
• Galapagos spinout Coultreon raises $125M for new take on SIK inhibition
  Coultreon Biopharma has raised $125 million from major biotech investors to advance its pipeline targeting SIK inhibition for autoimmune diseases. This funding will support the development of therapies that could streamline treatment approaches in this area.
• Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.
  A growing number of young biotechs are proving they can profitably sell their own medicines rather than relying on acquisitions. This trend could reshape investor interest in the sector, as companies like BridgeBio (BBIO) and Madrigal (MDGL) demonstrate commercial viability.
• Boehringer, Zealands obesity shot looks as good as Novo's Wegovy but weaker than Lilly's Zepbound
  Boehringer Ingelheim's obesity therapy demonstrated nearly 17% weight loss after 18 months, comparable to Novo Nordisk's Wegovy but not as effective as Lilly's Zepbound. The competitive landscape in obesity treatments continues to evolve with these promising results.
• Revolution Medicines rival Erasca falls after early-stage trial data for cancer therapy
  Erasca's stock dipped following the release of early-stage trial data for its cancer therapy, which did not meet investor expectations. This comes as Revolution Medicines' recent developments have renewed interest in pancreatic cancer treatments.

Quick hits

• Novo Nordisk gains Fast Track status for coramitug to treat ATTR amyloidosis.
• AstraZenecas Breztri wins U.S. approval for asthma treatment.
• Intellia Therapeutics CEO discusses Phase 3 CRISPR readout and next steps.

Read the full briefing →

]]> Biotech https://burns-media.com/biotech/archive/2026-04-27 https://burns-media.com/biotech/archive/2026-04-27 Mon, 27 Apr 2026 07:00:00 +0000 Positive results could pave the way for FDA approval. Intellia's CRISPR therapy just became the first of its kind to succeed in a Phase 3 trial, setting the stage for a potential FDA approval. This breakthrough could reshape treatment options for hereditary angioedema patients.

Top stories

• Intellia's in vivo CRISPR therapy first to succeed in Phase 3
  Intellia's CRISPR-based treatment for hereditary angioedema showed significant efficacy in reducing swelling attacks during its Phase 3 trial, marking a pivotal moment for gene-editing therapies. The success could lead to an FDA approval, enhancing Intellia's competitive position against established therapies like Takeda's Takhzyro (TAK-441).
• Sun Pharma to buy Organon for $11.75B in major portfolio expansion
  Sun Pharma has agreed to acquire Organon for $11.75 billion in an all-cash deal, significantly expanding its portfolio in women's health and biosimilars. The acquisition price translates to $14 per share, reflecting Sun's strategy to enhance its market position post-merger.
• Oruka’s long-acting psoriasis therapy posts strong results in mid-stage study
  Oruka Therapeutics reported that its long-acting injectable treatment for plaque psoriasis achieved complete skin clearance in 63% of patients during a mid-stage trial. This success could position Oruka favorably against existing therapies like AbbVie’s Humira and other biologics.

Quick hits

• Ligand Pharmaceuticals is set to acquire XOMA Royalty in a $740M all-cash deal.
• Motif Neurotech receives FDA approval to begin feasibility trials for a brain implant aimed at treating depression.
• Investment in UK biotechs shows early signs of recovery, with Q1 2026 equity funding rising significantly.

Read the full briefing →

]]> Biotech https://burns-media.com/biotech/archive/2026-04-22 https://burns-media.com/biotech/archive/2026-04-22 Wed, 22 Apr 2026 07:00:00 +0000 Sanofi's Tzield approved for young children; Roche's MS drug data raises safety concerns. Sanofi's Tzield now treats type 1 diabetes in children as young as one, expanding its market significantly. Meanwhile, Roche's new MS drug shows efficacy but raises liver toxicity concerns.

Top stories

• FDA expands Sanofi’s Tzield use to children as young as 1 for type 1 diabetes delay
  The FDA's approval allows Tzield to be administered to children aged one and older, broadening its potential patient base. Tzield is designed to delay the onset of type 1 diabetes, a significant market with unmet needs.
• Roche’s multiple sclerosis pill delays relapse, but liver toxicity could need monitoring
  Roche's fenebrutinib demonstrated a more than two-fold increase in relapse-free interval compared to Sanofi's Aubagio. However, safety concerns regarding liver toxicity may complicate its approval process.
• Merck gains approval of HIV drug regimen Idvynso
  Merck's Idvynso, a once-daily HIV regimen, received FDA approval, marking a significant addition to the HIV treatment landscape. This approval comes as many biotechs are exiting the HIV market.
• Kyverna Therapeutics plans to submit cell therapy for stiff person syndrome for FDA approval
  Kyverna's one-time cell therapy has shown promising results in improving mobility and reducing disabilities in patients with stiff person syndrome. The company is preparing for an FDA submission, which could expedite its market entry.
• Cosmo Pharma Eyes 2027 NDA for Baldness Candidate After Positive Phase III 12-Month Data
  Cosmo Pharma's clascoterone showed long-term safety and continued efficacy in a Phase III trial for hair loss, supporting its potential NDA submission in 2027. The drug targets the underlying biology of hair loss.

Quick hits

• Moderna continues its bird flu vaccine study but limits U.S. work.
• BioAge reports early data suggesting 'best-in-class' potential for its inflammation drug targeting NLRP3.
• Judge postpones Purdue Pharma's sentencing to allow opioid victims to attend.

Read the full briefing →

]]> Biotech https://burns-media.com/biotech/archive/2026-04-21 https://burns-media.com/biotech/archive/2026-04-21 Tue, 21 Apr 2026 07:00:00 +0000 Roche's fenebrutinib delays MS relapses but raises liver toxicity issues. Roche's fenebrutinib doubled relapse-free intervals in MS patients compared to Sanofi's Aubagio. However, potential liver toxicity may complicate its regulatory path.

Top stories

• #AAN26: Roche’s multiple sclerosis pill delays relapse, but liver toxicity could need monitoring
  Roche's fenebrutinib increased the relapse-free interval for multiple sclerosis patients by over 100% compared to Sanofi's Aubagio, but safety concerns regarding liver toxicity were raised during the presentation. The data positions Roche to seek FDA approval, yet the safety profile could influence regulatory decisions.
• Kyverna Therapeutics plans to submit cell therapy for stiff person syndrome for FDA approval
  Kyverna's one-time cell therapy showed promising results in improving mobility and reducing disabilities in patients with stiff person syndrome during late-stage trials. The company aims to submit its application to the FDA in the coming months, potentially marking a significant advancement in treatment options for this rare disease.
• Merck gains approval of HIV drug regimen Idvynso
  Merck's Idvynso has been approved as a new HIV drug regimen, enhancing its portfolio in the competitive HIV treatment market. This approval reflects Merck's ongoing commitment to addressing unmet needs in HIV therapy, which could bolster its market share against competitors like Gilead (GILD).
• Medicare indefinitely delays pilot plan to cover weight loss drugs
  The Centers for Medicare and Medicaid Services has postponed a pilot program for obesity medications due to lack of participation from insurance plans. This delay could impact drug manufacturers like Novo Nordisk (NVO) and Eli Lilly (LLY), which have been anticipating expanded coverage for their weight loss products.
• Alzheimer’s Linked to Cancer Mutations in Brain Immune Cells
  Research indicates that cancer-driving mutations in microglia, the brain's immune cells, may contribute to Alzheimer's disease development. This discovery opens avenues for new therapeutic strategies targeting these mutations, potentially benefiting companies focused on neurodegenerative diseases.

Quick hits

• Amazon One Medical launches a new GLP-1 management program for weight loss.
• Cosmo Pharma eyes a 2027 NDA for baldness candidate clascoterone after positive Phase III data.
• Merck's Welireg fails to improve outcomes in first-line kidney cancer, marking a significant setback.

Read the full briefing →

]]> Biotech https://burns-media.com/biotech/archive/2026-04-20 https://burns-media.com/biotech/archive/2026-04-20 Mon, 20 Apr 2026 07:00:00 +0000 Nektar's promising mid-stage trial results may lead to a Phase 3 study. Nektar Therapeutics' recent mid-stage trial data on alopecia therapy shows extended hair growth, nearly meeting Wall Street expectations. This positions the company to advance into Phase 3 trials.

Top stories

• Nektars long-term mid-stage alopecia data fuels Phase 3 plans
  Nektar's rezpegaldesleukin drug demonstrated promising results in its extension phase, promoting hair growth in alopecia patients. The company plans to leverage this data to initiate a Phase 3 trial, potentially positioning it against competitors like Eli Lilly and their hair loss treatments.
• Pfizer, Astellas win FDA priority review for Padcev in bladder cancer
  The FDA has granted priority review status for the combination of Padcev and Keytruda in treating bladder cancer, a significant step for both Pfizer (PFE) and Astellas. A decision is expected by Q3 2026, which could enhance their market positioning against competitors like Merck.
• Novo Nordisks sickle cell therapy hits in Phase 3, but data lag expectations
  Novo Nordisk's etavopivat successfully reduced sickle cell disease symptoms in its Phase 3 trial, but the results fell short of the company's previous expectations. Analysts are now cautious about the drug's market entry timeline and competitive positioning against other therapies.
• Stat+: A controversy over research monkeys highlights ambiguity over health standards
  A leading animal rights group is accusing Pfizer of running afoul of its own standards in the handling of research monkeys. This controversy may impact Pfizer's reputation and regulatory scrutiny moving forward.

Quick hits

• Nektar's mid-stage alopecia data shows promise for hair growth, potentially leading to a Phase 3 trial.
• Novo Nordisk's etavopivat shows efficacy in Phase 3, but data falls short of expectations.
• Theramex exits U.K.'s self-regulatory body after compliance failures, raising industry concerns.

Read the full briefing →

]]> Biotech https://burns-media.com/biotech/archive/2026-04-18 https://burns-media.com/biotech/archive/2026-04-18 Sat, 18 Apr 2026 07:00:00 +0000 UCB's acquisition diversifies its epilepsy treatment portfolio amid rising competition. UCB is set to acquire Neurona for up to $1.2B, aiming to enhance its portfolio in seizure therapies. This move comes as competition intensifies in the epilepsy treatment market.

Top stories

• UCB, betting on seizure cell therapy, to buy Neurona for up to $1.2B
  UCB's acquisition of Neurona will bolster its offerings in treating epilepsy, specifically targeting hard-to-treat forms. The deal includes an upfront payment along with milestone payments based on Neurona's future performance.
• Trump issues executive order on psychedelic drugs
  Former President Trump signed an executive order aimed at easing restrictions on psychedelic research and therapies, potentially opening new avenues for companies in this emerging sector. This could lead to increased funding and regulatory support for clinical trials.
• RevMed’s stunning success; FDA to reclassify peptides; and more
  Revolution Medicines reported groundbreaking results from its pan-RAS drug, significantly improving survival in pancreatic cancer patients. The FDA is also considering reclassifying peptides, which could impact various biotech companies involved in peptide therapies.
• Targeted Gene Delivery Calms Lung Inflammation in Respiratory Infection Mouse Models
  A new lung-targeted gene delivery method has shown promise in reducing inflammation and tissue damage in infected mice, potentially leading to more precise treatments for severe respiratory infections. This innovation could pave the way for new therapies that avoid systemic immune effects.
• Novo obesity drug outperforms Lilly’s in preserving lean body mass: study
  Novo Nordisk's new obesity treatment demonstrated superior efficacy in preserving lean body mass compared to Eli Lilly's competing product, which could shift market dynamics in the obesity drug sector. This finding may influence prescribing patterns and patient outcomes.

Quick hits

• Alamar's stock surged 40% following an upsized IPO, raising significant capital for growth.
• Kailera Therapeutics raised $625 million in its IPO, focusing on obesity treatments.
• FDA is reviewing new data on testosterone therapy, potentially expanding its indications for libido enhancement.

Read the full briefing →

]]> Biotech https://burns-media.com/biotech/archive/2026-04-17 https://burns-media.com/biotech/archive/2026-04-17 Fri, 17 Apr 2026 07:00:00 +0000 UCB's acquisition of Neurona marks a strategic move into cell therapy for epilepsy. In today's briefing, UCB's significant acquisition of Neurona highlights a strategic expansion in their epilepsy treatment portfolio. This move could reshape the landscape for seizure therapies.

Top stories

• UCB to Acquire Neurona for Up to $1.2B, Expanding Epilepsy Treatments
  UCB has announced plans to acquire Neurona for up to $1.2 billion, aiming to diversify its offerings in seizure treatments with a promising cell therapy currently in early testing. This acquisition aligns with UCB's strategy to enhance its pipeline for hard-to-treat forms of epilepsy. Investors will be watching closely to see how this integration impacts UCB's growth and innovation in the neurology space.
• Revolution Medicines' Pancreatic Cancer Breakthrough Boosts Valuation
  Revolution Medicines has reported successful Phase 3 results for its targeted 'pan-RAS' drug, which significantly improved survival rates in patients with recurrent pancreatic cancer. This data has reportedly increased the company's buyout price, reflecting heightened interest from potential acquirers. The results position Revolution as a key player in the oncology space, particularly for hard-to-treat cancers.
• Targeted Gene Delivery Shows Promise in Lung Inflammation Treatment
  Recent studies demonstrated that a lung-targeted gene delivery system effectively reduced harmful inflammation in mouse models of respiratory infection, without triggering systemic immune responses. This approach could pave the way for more precise therapies for severe infections, addressing a significant clinical need. Researchers are optimistic about the potential applications in human medicine, particularly for respiratory diseases.
• Kailera Therapeutics Raises $625M in Record-Setting IPO
  Kailera Therapeutics successfully raised $625 million through its IPO on Nasdaq, pricing shares at $16 each. Backed by Bain Capital Life Sciences, Kailera aims to advance its pipeline focusing on obesity treatments. This significant capital influx positions Kailera to accelerate its development efforts in a competitive market.
• FDA Prepares for GDUFA IV Reauthorization, Implications for Generic Drugs
  The FDA is gearing up for the fourth reauthorization of the Generic Drug User Fee Amendments (GDUFA), with information being made available for industry stakeholders. This reauthorization process is crucial for ensuring the continued efficiency and effectiveness of the generic drug approval process. Stakeholders will be keen to understand the implications of any changes that may arise from this reauthorization.

Quick hits

• Alamar Therapeutics sees a 40% increase following its upsized IPO.
• Novo Nordisk's obesity drug outperforms Lilly's in preserving lean body mass.
• FDA eyes expanding testosterone therapy for libido based on new research.

Read the full briefing →

]]> Biotech https://burns-media.com/biotech/archive/2026-04-12 https://burns-media.com/biotech/archive/2026-04-12 Sun, 12 Apr 2026 07:00:00 +0000 Replimune faces regulatory challenges as FDA denies melanoma treatment again. In a significant setback for Replimune, the FDA has rejected its melanoma candidate RP1 for the second time. This decision underscores ongoing regulatory scrutiny in drug approvals.

Top stories

• FDA Rejects Replimune's Melanoma Prospect for Second Time
  The FDA has once again denied Replimune's application for its melanoma drug RP1 due to unresolved issues with the study results. This marks a critical moment for the company as it struggles to meet regulatory expectations, which could impact its future funding and strategic direction. Investors should watch for potential implications on Replimune's stock as the company navigates these challenges.

Quick hits

• Oricell raises over $110M for CAR-T therapy targeting solid tumors ahead of an IPO.
• Lilly launches Foundayo, a GLP-1 oral medication, entering a competitive obesity market.
• Avalyn plans an IPO to fund phase 3 trials for inhaled versions of respiratory drugs.

Read the full briefing →

]]> Biotech